100results about "Calcium binding proteins" patented technology

The invention relates to a biomarker combination for clinical benefit of non-small cell lung cancer immunotherapy and application of the biomarker combination. The biomarker for predicting the clinical benefit of the non-small cell lung cancer immunotherapy comprises an immune globulin kappa light chain variable region 1-27 (IGKV1-27), a human leukocyte antigen H (HLA-H), an S100 calcium binding protein A8 (S100A8), a chromogranin A (CHGA), an elastin (ELN) and a nephronectin (NPNT). The biomarkers for predicting the clinical benefit of the immunotherapy of the non-small cell lung cancer can be detected, and the clinical benefit effect of the immunotherapy of the non-small cell lung cancer of a patient is judged by the markers.

The invention relates to the technical field of biomedicine, in particular to an umbilical cord mesenchymal stem cell exosome and a preparation method and application thereof.The umbilical cord mesenchymal stem cell exosome is derived from umbilical cord mesenchymal stem cells expressing S100g-MTOR binding domain fusion protein and can inhibit excessive autophagy through an S100g / MTOR signal channel, and therefore intestinal mucosal barrier damage caused by antibiotics is relieved. The preparation method comprises the following steps: constructing an expression vector, transfecting and screening a stable expression cell strain, performing serum-free culture, collecting a culture supernatant, purifying the exosome and the like. The exosome disclosed by the invention can be used for preparing a medicine for treating antibiotic-related intestinal mucosal barrier injury, has the advantages of strong targeting property, definite action mechanism, remarkable curative effect and the like, and provides a new choice for preventing and treating antibiotic-related intestinal adverse reactions.

A modified myoferlin protein capable of being packaged into extracellular vesicles (EVs) to facilitate release of EV payloads into recipient cells. The modified myoferlin protein enhances the release of payload at the targeted site. The present invention further provides a modified myoferlin-encapsulating nanoparticle comprising an exosome encapsulating any embodiment of the modified myoferlin of the present invention and one or more cargo RNAs to enhance release of the cargo RNAs at the targeted site.

The invention relates to the field of biological medicine, in particular to application of S100A9 in treatment or detection of diabetic cardiomyopathy. The research finds that the expression of S100A9 in the heart tissue of a diabetic cardiomyopathy mouse is obviously increased. Overexpression of the S100A9 can aggravate myocardial injury and cardiac dysfunction, and inhibition of expression or activity of the S100A9 can improve illness conditions. Both the S100A9 inhibitor paquinimod and the macrophage scavenger chlorophosphonate liposome can reduce the concentration of S100A9 in serum, relieve cardiac enlargement and myocardial fibrosis and recover the left ventricular ejection fraction. In addition, the S100A9 can be used as a marker for detecting the diabetic cardiomyopathy, and related detection products can reflect the severity of the illness state by detecting the expression quantity of the S100A9 in tissue cells or body fluid. The invention provides a new target spot, medicine and detection means for treatment and detection of diabetic cardiomyopathy.

Provided herein are compositions, systems, and methods for delivering an effector protein into a cell. The present disclosure, in some aspects, provide novel proteins delivering an effector protein into a cell. The novel proteins are supernegatively charged proteins derived from highly anionic proteins identified from the proteome (e.g., human proteome). The novel protein tags can be associated (e.g., covalently or nocovalently) with the protein to be delivered to facilitate delivery of the effector protein into a cell.

Novel nucleic acid sequences, vectors, modified cells, binding agents, peptides and pharmaceutical compositions are provided herein that are useful as a medicament, for example in the prevention or treatment of cancer or viral infections associated with impaired HLA class I antigen presentation. Corresponding methods and uses are also provided herein.

The invention discloses a method for extracting calreticulin from tissues and application. The tissue cell extract extracted by the method contains calreticulin and can be used for preparing drugs or vaccines for preventing cancers. Experimental results show that after the tissue cell extract is immunized for several weeks, specific immune response of an organism can be triggered, cancerous cells in the organism can be removed, and therefore the aim of preventing cancers is achieved. The tissue cell extract provided by the invention can be used as a tumor preventive vaccine for preventing autologous or allogenic tumors and reducing the incidence rate of cancers in healthy people.

The invention discloses a milk-derived polypeptide for promoting osteoblast proliferation and differentiation and application thereof, and belongs to the technical field of bioactive peptides. The invention provides a milk-derived bioactive peptide WLKPDPS. The milk-derived bioactive peptide WLKPDPS has extremely high biological safety and a function of promoting osteoblast proliferation and differentiation. The milk-derived bioactive polypeptide WLKPDPS disclosed by the invention has an obvious effect of promoting osteoblast proliferation, can obviously promote osteoblast mineralization, and is expected to be used for preparing medicines for promoting osteoblast proliferation and preventing osteoporosis. The milk-derived bioactive polypeptide WLKPDPS is convenient to synthesize, can be industrially produced, and has a good application prospect in the fields of foods, medicines, cosmetics and the like.

Provided herein are methods and cell systems for production of a recombinant antibody in cells in which the antibody is directed against a target protein that is natively expressed as an intracellular protein in the cell. Also provided herein are modified cell lines for use in such methods in which the modified cell line is engineered to express a variant target protein that has a mutant epitope of the target epitope of an antibody.

The chimeric signal peptide for protein expression comprises an N region, a hydrophobic region, and a C region, wherein the N region and the C region are from the same signal peptide of a first protein, and the hydrophobic region is from the signal peptide of a second protein, and the first protein is different from the second protein. The first and second proteins can be independently selected from the group consisting of BM40, IL2, HA, insulin, CD33, IFNA2, IgGK leader, AZU, and SEAP.

The present disclosure provides constructs comprising a coding sequence operably linked to a promoter which expresses the polynucleotide in an outer hair cell, wherein the coding sequence encodes a polypeptide (e.g., a heterologous polypeptide). Exemplary constructs include AAV constructs. Also provided are methods of using disclosed constructs for the treatment of hearing loss and / or deafness.

The invention relates to a mutant calreticulin for diagnosis of myeloid malignant tumors. A method for diagnosing myeloid malignancies comprising determining the presence of a mutant allele of a calreticulin gene is disclosed. In addition, genomic sequences, cDNA sequences, mRNA sequences and protein sequences of the mutant calreticulin are also subject matter of the invention. Furthermore, the invention relates to the medical use of inhibitors of the mutant calreticulin.

The present invention relates generally to methods for preventing and / or treating myeloproliferative disorders. More specifically, the myeloproliferative disorders are those associated with the presence of a frameshift mutation in the calreticulin (CALR) gene of a cell involved in the myeloproliferative disorders. The present invention also relates to immunological agents, such as antibodies, to calreticulin, methods for preventing and / or treating myeloproliferative diseases using the immunological agents, and chimeric antigen receptors having extracellular domains based on antibodies to calreticulin.

Novel chimeric peptides comprise an N-cadherin binding domain for binding N-cadherin, which is expressed on the surface of cells, in particular smooth muscle cells, and a fibronectin- binding domain, which binds surrounding extracellular matrix and a binding site for fibronectin. The chimeric peptides can be loaded on to nanoparticles, suitably degradable polar hydrophobic ionic polyurethane (D-PHI) nanoparticles for delivery, which can be incorporated into coatings for medical devices, including stents and balloons.

The present invention relates to peptides capable of binding to calprotectin. The present invention further relates to methods for the detection and purification of calprotectin.

Provided are a use of recombinant calreticulin in hair growth, hair breeding, hair protection or anti-hair loss and a related product. The recombinant protein is derived from the full length of calreticulin or a fragment thereof, and has the functions of treating hair loss and improving hair by means of injection or application. Therefore, calreticulin is expected to be developed into an effective method and means for treating hair loss and improving hair.

A low immunogenic exosome-based RNA package and delivery system capable of delivering a cargo RNA to a target site. In an embodiment, the low immunogenic exosome- based RNA package and delivery system comprises an exosome producing cell, one or more cargo RNA encoding plasmids and one or more fusion protein encoding plasmids, wherein the cargo RNA comprises a package RNA and a packaging domain and wherein the package fusion protein comprises an exosome associated transmembrane protein fused to a packaging protein. The present invention also provides an exosome composition comprising an exosome encapsulating a cargo RNA and a package fusion protein wherein the cargo RNA and the package fusion protein binds via the packaging domain and the packaging protein to form cargo RNA fusion protein complex. In an embodiment the packaging protein is endogenous to a subject. The present invention also provides a method of preparation of the exosome composition.

The presently claimed and described technology provides vaccine compositions comprising at least two mutant-calreticulin (CALR)-peptides, wherein the at least two peptides have overlapping sequences and methods for administration of the vaccine compositions to induce or elicit an antitumor response or improve or enhance antitumor T cell immunity and methods of preventing, treating, reducing, or slowing progression or development of a hematological malignancy in a subject with a calreticulin mutation.

Genetically encoded calcium indicator (GECI) polypeptides and the nucleic acid molecules encoding such polypeptides are provided.

The invention relates to a preparation method of an S100A6 protein with low endotoxin content, and the preparation method comprises the following steps: connecting an S100a6 gene into a pET-28a vector to obtain a pET-28a-S100a6 plasmid; introducing into Escherichia coli, carrying out induced expression, and centrifuging to obtain thalli containing S100A6 protein; cracking, crushing and centrifugally filtering the thalli to obtain a supernatant; performing nickel column purification and Q column chromatography purification on the supernatant to obtain a protein solution 2; and purifying with a desalting column to obtain the S100A6 protein. According to the preparation method, the endotoxin content lt can be obtained; the S100A6 protein can be used for researching the S100A6 protein or gene-related pathways and mechanisms in a living body, so that an effective scheme is provided for the treatment of diseases. The S100A6 protein can be applied to the research of the S100A6 protein or gene-related pathways and mechanisms in the living body. The invention further provides a regulation and control effect of the S100A6 receptor RAGE in CVB3 viral myocarditis, and a new target spot and a new treatment scheme are provided for development of drugs for treating the CVB3 viral myocarditis.

This invention discloses a lactobridged protein-derived calcium chelating peptide and its applications, belonging to the field of bioactive small molecule peptide technology. The calcium chelating peptide provided by this invention is safe and non-toxic, exhibiting better physicochemical activity compared to traditional calcium supplements. Its calcium chelating capacity reaches over 419.36 μg / mg, and it can promote calcium transport in the Caco-2 cell monolayer, thereby improving calcium absorption and bioavailability in the human body, making it suitable for use as a calcium supplement. This invention can develop a new protein source for calcium supplements and makes a significant contribution to the high-value utilization of dairy products.

The invention relates to peptides capable of binding calprotectin. The invention is further directed to methods of detecting and purifying calprotectin.

The invention provides a construction method of a CETN3 knockout cell line, a human brain organ with microhead deformity and application of the human brain organ, and belongs to the field of organoids. The CETN3-deficient stem cells prepared by the method provided by the invention still have normal multiplication capacity and differentiation potential, do not influence the development of organoid, can still develop into organoid with good morphology, but have reduced volume, which is similar to phenotypes appearing in small head malformation patients. The CETN3 knockout embryonic stem cell line is utilized, the cells can be self-organized into a structure similar to the human cerebral cortex through nerve induction and 3D culture, and the phenotype of a small head malformation patient is simulated. By utilizing the organ, the research on the disease mechanism can be promoted, and the medicine can be screened more effectively and conveniently.

The present invention provides novel nucleic acid sequences, vectors, modified cells, binding agents, peptides and pharmaceutical compositions that are useful as agents, for example, in the prevention or treatment of cancer or viral infections associated with impaired HLA class I antigen presentation. The invention further provides a corresponding method and application.

The present disclosure generally relates to systems and methods for treating and preventing diseases or conditions, such as aging, atherosclerosis, obesity, viral diseases, etc., which may be treated, according to some embodiments, by activation of an immune response in a subject. In some embodiments, for example, aging may be treated or prevented by removal of senescent cells by the immune system. In some embodiments, atherosclerosis may be treated or prevented by removal of plaque by the immune system. In some embodiments, obesity may be treated by removal of fat cells by the immune system. In some embodiments, viral diseases may be treated by removal of viruses by the immune system. Exemplary viral diseases include diseases caused by SARS-CoV-2 and HIV, among others.

The disclosure provides compositions containing polynucleotides that encode a stereocilin protein under regulatory control of an outer hair cell-specific promoter, as well as two-vector systems containing the same, that can be used to promote expression of stereocilin specifically in outer hair cells. Additionally, the compositions described herein may be used for the treatment of subjects having or at risk of developing hearing loss, such as hearing loss associated with a mutation in stereocilin.

The present disclosure provides constructs that include a coding sequence operably linked to a promoter that expresses a polynucleotide in an outer hair cell, the coding sequence encoding a polypeptide (e.g., a heterologous polypeptide). Exemplary constructs include AAV constructs. Also provided are methods of using the disclosed constructs for the treatment of hearing loss and / or hearing loss.

Provided herein are methods and compositions for treating and / or preventing recurrent Clostridium difficile infection (rCDI), neutropenia, cardiovascular disease (e.g., atherosclerosis and / or stroke), asthma, and / or cancer involving administering to a subject a pharmaceutical composition comprising a purified bacterial mixture.

Novel nucleic acid sequences, vectors, modified cells, binding agents, peptides and pharmaceutical compositions are provided herein that are useful as a medicament, for example in the prevention or treatment of cancer or viral infections associated with impaired HLA class I antigen presentation. Corresponding methods and uses are also provided herein.